Lotte Holdings Acquires Pharmaceutical Manufacturing Plant Worth 206 Billion KRW
[Asia Economy Reporter Lee Jung-yoon] Lotte Corporation announced on the 13th that it has decided to acquire a pharmaceutical manufacturing plant located in New York State, USA, from Bristol-Myers Squibb Company for 206 billion KRW. The purpose of the acquisition is to enter the bio sector and for investment, with the acquisition amount accounting for 0.01% of total assets.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Additionally, it announced an investment of 10.4 billion KRW in Lotte Biologics, a pharmaceutical manufacturing company. The purpose is to establish a new corporation for the bio new business. The company stated, "This is an investment in Lotte Biologics, a new corporation planned to be established for the bio new business."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
